Related Experiment Video
Updated: Mar 30, 2026

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
Soluble M6P/IGFIIR in the circulation
Carolyn D Scott1, Wieland Kiess2
1Kolling Institute of Medical Research, Royal North Shore Hospital and University of Sydney, Sydney, Australia.
Abstract:
Soluble M6P/IGFIIR has the potential to be a significant carrier of IGF-II and mannose 6-P proteins in the circulation and play an important role as an antagonist to the cellular receptor. Evidence suggests that soluble receptor plays a role in fetal and childhood growth by opposing the growth stimulatory effects of IGF-II. Maternal serum levels of M6P/IGFIIR are elevated in late pregnancy and the IGF-II:soluble M6P/IGFIIR ratio in cord blood correlates strongly with weight at birth and placental weight suggesting an important role in fetal growth and development. However, elevated soluble receptor levels may also be indicative of disease in later life, such as liver cirrhosis and some tumor types and may be a useful marker for monitoring treatment and progression of the disease. Further investigation of the regulation of this soluble receptor in health and disease is required to fully elucidate its role in the circulation.
Insights
Soluble Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor (M6P/IGFIIR) acts as a carrier for IGF-II and may influence fetal growth. Elevated levels are linked to birth weight and potentially disease later in life.
Area of Science:
- Endocrinology
- Molecular Biology
- Developmental Biology
Background:
- Soluble M6P/IGFIIR functions as a carrier for IGF-II and mannose 6-P proteins.
- It acts as an antagonist to the cellular M6P/IGFIIR, potentially opposing IGF-II's growth-stimulatory effects.
Purpose of the Study:
- To investigate the role of soluble M6P/IGFIIR in fetal growth and development.
- To explore the association of soluble M6P/IGFIIR levels with birth weight and placental weight.
- To examine the potential of soluble M6P/IGFIIR as a biomarker for disease and treatment monitoring.
Main Methods:
- Analysis of maternal serum and cord blood M6P/IGFIIR levels.
- Correlation studies between IGF-II:soluble M6P/IGFIIR ratio and anthropometric measurements (birth weight, placental weight).
- Review of existing evidence linking soluble M6P/IGFIIR to various disease states.
Main Results:
- Maternal serum M6P/IGFIIR levels increase in late pregnancy.
- The IGF-II:soluble M6P/IGFIIR ratio in cord blood strongly correlates with birth weight and placental weight.
- Elevated soluble M6P/IGFIIR levels are associated with liver cirrhosis and certain tumors.
Conclusions:
- Soluble M6P/IGFIIR plays a significant role in fetal growth regulation.
- It may serve as a useful biomarker for monitoring disease progression and treatment efficacy.
- Further research is needed to fully understand the regulation and function of soluble M6P/IGFIIR in health and disease.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Insulin: The Receptor and Signaling Pathways
PI3K/mTOR/AKT Signaling Pathway
Amplifying Signals via Second Messengers
TGF - β Signaling Pathway
IP3/DAG Signaling Pathway

